

Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 10 of 20 returned.☐ 1. Document ID: US 20050075489 A1**Using default format because multiple data bases are involved.**

L5: Entry 1 of 20

File: PGPB

Apr 7, 2005

PGPUB-DOCUMENT-NUMBER: 20050075489

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050075489 A1

TITLE: DSP-5 dual-specificity phosphatase

PUBLICATION-DATE: April 7, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 530/388.25

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 2. Document ID: US 20050058650 A1

L5: Entry 2 of 20

File: PGPB

Mar 17, 2005

PGPUB-DOCUMENT-NUMBER: 20050058650

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050058650 A1

TITLE: DSP-12 and DSP-13 dual-specificity phosphatases

PUBLICATION-DATE: March 17, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 424/146.1; 435/196, 435/320.1, 435/325, 435/6, 435/69.1, 530/388.26, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	--------

☐ 3. Document ID: US 20040077574 A1

L5: Entry 3 of 20

File: PGPB

Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040077574

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040077574 A1

TITLE: Modulation of biological signal transduction by RNA interference

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Klinghoffer, Richard	Seattle	WA	US	
Lewis, Stephen Patrick	Mountlake Terrace	WA	US	

US-CL-CURRENT: 514/44; 435/455, 536/23.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	--------

☐ 4. Document ID: US 20040043411 A1

L5: Entry 4 of 20

File: PGPB

Mar 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040043411

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040043411 A1

TITLE: DSP-11 dual-specificity phosphatase

PUBLICATION-DATE: March 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 435/6; 435/196, 435/320.1, 435/325, 435/69.1, 530/388.26, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	--------

☐ 5. Document ID: US 20030215899 A1

L5: Entry 5 of 20

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215899

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030215899 A1

TITLE: Reversible oxidation of protein tyrosine phosphatases

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Meng, Tzu-Ching	Oyster Bay	NY	US	
Tonks, Nicholas K.	Huntington	NY	US	
Cool, Deborah E.	Snohomish	WA	US	

US-CL-CURRENT: 435/21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KINC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 6. Document ID: US 20030175829 A1

L5: Entry 6 of 20

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175829
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175829 A1

TITLE: DSP-4 dual-specificity phosphatase

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 435/7.9; 435/196, 530/388.26

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KINC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 7. Document ID: US 20030138931 A1

L5: Entry 7 of 20

File: PGPB

Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030138931
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030138931 A1

TITLE: DSP-10 dual-specificity phosphatase

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 435/194; 435/196, 435/320.1, 435/325, 435/69.1, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 8. Document ID: US 20030119045 A1

L5: Entry 8 of 20

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119045

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030119045 A1

TITLE: DSP-9 dual-specificity phosphatase

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 435/6; 424/146.1, 435/196, 435/320.1, 435/69.1, 435/7.2, 435/91.2,
514/44, 530/388.26, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 9. Document ID: US 20030092114 A1

L5: Entry 9 of 20

File: PGPB

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092114

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030092114 A1

TITLE: DSP-18 dual-specificity phosphatase

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 435/69.1; 435/196, 435/320.1, 435/325, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	--------

☐ 10. Document ID: US 20020182203 A1

L5: Entry 10 of 20

File: PGPB

Dec 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020182203

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020182203 A1

TITLE: DSP-15 dual-specificity phosphatase

PUBLICATION-DATE: December 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 424/94.6; 435/196, 435/320.1, 435/325, 435/69.1, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	--------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L3 and substrate trapping mutant	20

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 11 through 20 of 20 returned.

☐ 11. Document ID: US 20020137170 A1

Using default format because multiple data bases are involved.

L5: Entry 11 of 20

File: PGPB

Sep 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020137170

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020137170 A1

TITLE: DSP-16 dual-specificity phosphatase

PUBLICATION-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 435/196; 435/320.1, 435/325, 435/69.1, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	--------

☐ 12. Document ID: US 20020102693 A1

L5: Entry 12 of 20

File: PGPB

Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102693

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020102693 A1

TITLE: DSP-14 dual-specificity phosphatase

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	

US-CL-CURRENT: 435/196; 435/320.1, 435/325, 435/69.1, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	--------

☐ 13. Document ID: US 20010049358 A1

L5: Entry 13 of 20

File: PGPB

Dec 6, 2001

PGPUB-DOCUMENT-NUMBER: 20010049358
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010049358 A1

TITLE: DSP-12 and DSP-13 dual-specificity phosphatases

PUBLICATION-DATE: December 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Luche, Ralf M.	Seattle	WA	US	
Wei, Bo	Kirkland	WA	US	

US-CL-CURRENT: 514/12; 435/196, 435/325, 435/6, 435/69.1, 435/7.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWAC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 14. Document ID: US 6852520 B1

L5: Entry 14 of 20

File: USPT

Feb 8, 2005

US-PAT-NO: 6852520
DOCUMENT-IDENTIFIER: US 6852520 B1

TITLE: DSP-2 dual-specificity phosphatase

DATE-ISSUED: February 8, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luche; Ralf M.	Seattle	WA		
Wei; Bo	Kirkland	WA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/325, 435/366, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWAC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 15. Document ID: US 6841369 B1

L5: Entry 15 of 20

File: USPT

Jan 11, 2005

US-PAT-NO: 6841369
DOCUMENT-IDENTIFIER: US 6841369 B1

TITLE: DSP-4 dual specificity phosphatase

DATE-ISSUED: January 11, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luche; Ralf M.	Seattle	WA		
Wei; Bo	Kirkland	WA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/6, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 16. Document ID: US 6825021 B2

L5: Entry 16 of 20

File: USPT

Nov 30, 2004

US-PAT-NO: 6825021

DOCUMENT-IDENTIFIER: US 6825021 B2

TITLE: DSP-15 dual-specificity phosphatase

DATE-ISSUED: November 30, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luche; Ralf M.	Seattle	WA		
Wei; Bo	Kirkland	WA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/440, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 17. Document ID: US 6649391 B1

L5: Entry 17 of 20

File: USPT

Nov 18, 2003

US-PAT-NO: 6649391

DOCUMENT-IDENTIFIER: US 6649391 B1

TITLE: DSP-11 dual-specificity phosphatase

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luche; Ralf M.	Seattle	WA		
Wei; Bo	Kirkland	WA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/6, 530/300, 530/350, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 18. Document ID: US 6645753 B1

L5: Entry 18 of 20

File: USPT

Nov 11, 2003

US-PAT-NO: 6645753

DOCUMENT-IDENTIFIER: US 6645753 B1

**** See image for Certificate of Correction ****TITLE: DSP-5 dual-specificity phosphatase

DATE-ISSUED: November 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luche; Ralf M.	Seattle	WA		
Wei; Bo	Kirkland	WA		

US-CL-CURRENT: 435/252.3; 435/196, 435/320.1, 435/6, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 19. Document ID: US 6551810 B1

L5: Entry 19 of 20

File: USPT

Apr 22, 2003

US-PAT-NO: 6551810

DOCUMENT-IDENTIFIER: US 6551810 B1

**** See image for Certificate of Correction ****TITLE: DSP-10 dual-specificity phosphatase

DATE-ISSUED: April 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luche; Ralf M	Seattle	WA		
Wei; Bo	Kirkland	WA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/325, 435/6, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 20. Document ID: US 6492157 B1

L5: Entry 20 of 20

File: USPT

Dec 10, 2002

US-PAT-NO: 6492157

DOCUMENT-IDENTIFIER: US 6492157 B1

TITLE: DSP-9 dual-specificity phosphatase

DATE-ISSUED: December 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luche; Ralf M.	Seattle	WA		
Wei; Bo	Kirkland	WA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/325, 536/23.1, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L3 and substrate trapping mutant	20

Display Format: [Previous Page](#)[Next Page](#)[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#) [Previous Doc](#) [Next Doc](#) [Go to Doc#](#)



Generate Collection

Print

L5: Entry 17 of 20

File: USPT

Nov 18, 2003

US-PAT-NO: 6649391

DOCUMENT-IDENTIFIER: US 6649391 B1

TITLE: DSP-11 dual-specificity phosphatase

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luche; Ralf M.	Seattle	WA		
Wei; Bo	Kirkland	WA		

US-CL-CURRENT: 435/196; 435/252.3, 435/320.1, 435/6, 530/300, 530/350, 536/23.2

CLAIMS:

What is claimed is:

1. An isolated polynucleotide that encodes a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2.
2. An isolated polynucleotide comprising the sequence set forth in SEQ ID NO:1.
3. An isolated polynucleotide that encodes a polypeptide capable of dephosphorylating an activated MAP-kinase, said polynucleotide comprising a sequence at least 80% identical to a polynucleotide that encodes a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2.
4. An isolated polynucleotide that encodes a polypeptide capable of dephosphorylating an activated MAP-kinase, said polynucleotide comprising a sequence at least 90% identical to a polynucleotide that encodes a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2.
5. An isolated polynucleotide that encodes a polypeptide capable of dephosphorylating an activated MAP-kinase, said polypeptide comprising an amino acid sequence of SEQ ID NO:2, wherein an aspartic acid is located at position 65 and the peptide sequence VGVHICALGFGRTGTMLACYLV (SEQ ID NO:3) is located at positions 91 through 111 of SEQ ID NO:2, wherein said polynucleotide comprises a sequence at least 80% identical to a polynucleotide that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
6. An isolated polynucleotide that encodes a polypeptide capable of dephosphorylating an activated MAP-kinase, said polypeptide comprising an amino acid sequence of SEQ ID NO:2, wherein aspartic acid is located at position 65 of SEQ ID NO:2 and the peptide sequence VGVHICALGFGRTGTMLACYLV (SEQ ID NO:3) is located at positions 91 through 111 of SEQ ID NO:2, wherein said

polynucleotide comprises a sequence at least 90% identical to a polynucleotide that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.

7. An expression vector comprising a polynucleotide according to any one of claims 1-2 and 3-6.

8. A host cell transformed or transfected with an expression vector according to claim 7.

9. An isolated polynucleotide that detectably hybridizes to a polynucleotide having a sequence that is the complement of the sequence set forth in SEQ ID NO:1 under moderately stringent conditions that include a wash in 0.1.times.SSC and 0.1% SDS at 50.degree. C. for 15 minutes, wherein said isolated polynucleotide exhibits at least 80% nucleotide identity to a polynucleotide comprising the sequence set forth in SEQ ID NO:1, and wherein said isolated polynucleotide encodes a polypeptide capable of dephosphorylating an activated Map-Kinase.

10. An expression vector comprising a polynucleotide according to claim 9.

11. A host cell transformed or transfected with an expression vector according to claim 10.

12. A method of producing a DSP-11 polypeptide, comprising the steps of: (a) culturing a host cell according to claim 8 under conditions that permit expression of the DSP-11 polypeptide; and (b) isolating DSP-11 polypeptide from the host cell culture.

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Monday, May 09, 2005

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L5	L3 and substrate trapping mutant	20
<input type="checkbox"/>	L4	L3 and substrate trapping mtant	0
<input type="checkbox"/>	L3	l2 and MAP-kinase	43
<input type="checkbox"/>	L2	L1 and DNA	345
<input type="checkbox"/>	L1	dual specificity phosphatase	399

END OF SEARCH HISTORY

=> file medline caplus biosis embase scisearch biotechds		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 16:01:04 ON 09 DEC 2002

FILE 'CAPLUS' ENTERED AT 16:01:04 ON 09 DEC 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:01:04 ON 09 DEC 2002
 COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 16:01:04 ON 09 DEC 2002
 COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:01:04 ON 09 DEC 2002
 COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'BIOTECHDS' ENTERED AT 16:01:04 ON 09 DEC 2002
 COPYRIGHT (C) 2002 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

=> s dsp-11 or dsp-11 polypeptide or dual specificity polypeptide?)
 UNMATCHED RIGHT PARENTHESIS 'LYPEPTIDE?)'
 The number of right parentheses in a query must be equal to the
 number of left parentheses.

=> s dsp-11 or dsp-11 polypeptide or dual specificity polypeptide?
 L1 10 DSP-11 OR DSP-11 POLYPEPTIDE OR DUAL SPECIFICITY POLYPEPTIDE?

=> dup rem l1
 PROCESSING COMPLETED FOR L1
 L2 10 DUP REM L1 (0 DUPLICATES REMOVED)

=> s (dsp-11 or dsp-11 polypeptide or dual specificity polypeptide?)
 L3 10 (DSP-11 OR DSP-11 POLYPEPTIDE OR DUAL SPECIFICITY POLYPEPTIDE?)

=> dup rem l3
 PROCESSING COMPLETED FOR L3
 L4 10 DUP REM L3 (0 DUPLICATES REMOVED)

=> d l4 1-10 ibib ab

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2001:64167 CAPLUS
 DOCUMENT NUMBER: 134:126840
 TITLE: Protein and cDNA sequences of a novel human protein
 DSP-11 with dual-specificity MAP
 kinase phosphatase activity, and therapeutic uses
 thereof
 INVENTOR(S): Luche, Ralf M.; Wei, Bo
 PATENT ASSIGNEE(S): Ceptyr, Inc., USA
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2001005983 A1 20010125 WO 2000-US19710 20000719

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1200602 A1 20020502 EP 2000-950452 20000719

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.:

US 1999-144557P P 19990720

WO 2000-US19710 W 20000719

AB The invention provides protein and cDNA sequences of a novel human protein **DSP-11**, which has sequences homol. with dual-specificity MAP kinase phosphatase. The protein **DSP-11** may be used, for example, to identify antibodies and other agents that inhibit **DSP-11** activity. North blotting results show significantly higher levels of **DSP-11** mRNA in tissues of human kidney and liver. The invention further relates to the uses of protein **DSP-11** for modulating cell proliferation, differentiation and survival. In addn., the invention also provides protein and cDNA sequences of a mouse **DSP-11** variant.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 BIOTECHDS COPYRIGHT 2002 THOMSON DERWENT AND ISI

ACCESSION NUMBER: 2002-01808 BIOTECHDS

TITLE: New human **dual specificity**

polypeptides and nucleic acids for diagnosis of disease and treatment of e.g. liver disorders;
vector-mediated gene transfer and expression in mammal cell, antibody, ribozyme, antisense triple helix and transgenic animal for gene therapy

AUTHOR: Meyers R A

PATENT ASSIGNEE: Millennium-Pharm.

LOCATION: Cambridge, MA, USA.

PATENT INFO: WO 2001073059 4 Oct 2001

APPLICATION INFO: WO 2001-US9477 23 Mar 2001

PRIORITY INFO: US 2000-191858 24 Mar 2000

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2001-611635 [70]

AB An isolated nucleic acid (I, human 21117 cDNA with a 3,554, 1,998, 1,114 or 672 bp DNA sequence fully defined) encoding a dual specificity phosphatase (human 38692 cDNA) with a 666 or 223 amino acid protein sequence fully defined is claimed. Also claimed are: a mammal host cell containing (I); an antibody that binds to (II); production of (II) by culturing the host cell and recovering (II) from the culture medium; detection of (II) in a sample using the antibody; a method for modulating the activity or expression of (II) using a compound (antibody); modulating the proliferation, survival or differentiation of a 38692 or 21117-expressing cell by contacting the cells with a compound (peptide, phosphopeptide, antibody, antisense, ribozyme, triple helix and/or nucleic acid) that modulates (II); transgenic animals; and prevention or therapy of a disorder caused by aberrant activity or expression of (I) or (II). The antibody can be used for the detection of (II) and the nucleic acids for detecting (I) for diagnosing diseases. The above is important for hematopoietic, liver or cellular proliferative or differentiative disorder diagnosis and gene therapy.

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:207549 CAPLUS
DOCUMENT NUMBER: 129:77541
TITLE: Gene structure and expression analysis of the drought-
and abscisic acid-responsive CDeT11-24 gene family
from the resurrection plant *Craterostigma plantagineum*
AUTHOR(S): Velasco, Riccardo; Salamini, Francesco; Bartels,
Dorothea
CORPORATE SOURCE: Max-Planck-Inst. Zuechtungsforschung, Cologne,
D-50829, Germany
SOURCE: Planta (1998), 204(4), 459-471
CODEN: PLANAB; ISSN: 0032-0935
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In order to understand the mol. mechanisms which are responsible for desiccation tolerance in the resurrection plant *Craterostigma plantagineum* a thorough anal. of the CDeT11-24 gene family was performed. CDeT11-24 comprises a small gene family whose genes are expressed in response to dehydration, salt stress and abscisic acid (ABA) treatment in leaves. The gene products are constitutively expressed in roots and disappear only when the plants are transferred to water. It is therefore suggested that the proteins are involved in sensing water status. The predicted proteins are very hydrophilic; they share some features with late-embryogenesis-abundant proteins, and sequence similarities were found with two ABA- and drought-regulated *Arabidopsis* genes. The anal. of .beta.-glucuronidase reporter genes driven by the CDeT11-24 promoter showed high activity in mature seeds in both transgenic *Arabidopsis* and tobacco. In vegetative tissues the promoter activity in response to ABA was restricted to young *Arabidopsis* seedlings. The responsiveness to ABA during later developmental stages was regained in the presence of the *Arabidopsis* gene product ABI3. Dehydration-induced promoter activity was only obsd. in *Arabidopsis* leaves at a particular developmental stage. This anal. indicates that some components in the signal transduction pathway of the resurrection plant are not active in tobacco or *Arabidopsis*.

L4 ANSWER 4 OF 10 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1997:512250 BIOSIS
DOCUMENT NUMBER: PREV199799811453
TITLE: Immunocytochemistry on the Thinprep processor.
AUTHOR(S): Dabbs, David J. (1); Abendroth, Catherine S.; Grenko,
Ronald T.; Wang, Xiaohong; Radcliffe, Gail E.
CORPORATE SOURCE: (1) Dep. Pathol., Pennsylvania State Univ., Coll. Med.,
P.O. Box 850, Hershey, PA 17033 USA
SOURCE: Diagnostic Cytopathology, (1997) Vol. 17, No. 5, pp.
388-392.
ISSN: 8755-1039.
DOCUMENT TYPE: Article
LANGUAGE: English

AB Introduction: For cytologic specimens, the vast majority of immunocytochemical studies (ICC) are performed on non-gynecologic specimens for diagnostic purposes, and they can be performed on unstained or previously stained direct smears. Although the ThinPrep processor (TPP) has been approved for the preparation of non-gynecologic specimens, there is scant literature describing the utility of ICC methodology on cytology specimens fixed and processed by this method. Materials and Methods: Forty-one fresh specimens were obtained from the surgical gross room and aspirated or scraped to collect cells for thin layer (TL) and direct smears (DS). Specimens included a variety of neoplastic and nonneoplastic samples that were either Papanicolaou (P) stained or unstained (US). One group of US TL slides was subjected to antigen retrieval (AR). Staining was graded semiquantitatively. Each sample acted as its own control. Antibodies (abs) included: CAM5.2, AE1/3, K903, vimentin, MSA, desmin,

s-100, HMB45, PSA, PAP, chromogranin, NSE, insulin, synaptophysin, pCEA, mCEA, mCEAD14, LCA, L26. UCHL-1, OPD-4, thyroglobulin, GCDFP, ER/PR, laminin, collagen IV, PLAP, HCG, CD68, HAM56, and MAC387. Results: Semiquantitative staining overall results comparisons: TLP gt DSP, (11/25), 44%; TLP lt DSP, (6/25), 24%; TLP = DSP, (8/25), 32%; TLUS gt DSUS, (9/24), 38%; TLUS lt DSUS, (3/24), 12%; TLUS = DSUS, (12/24), 50%; The results of TLP vs. TLUS were: TLP gt TLUS, (8/41), 20%; TLP lt TLUS, (9/41), 22%; TLP = TLUS, (24/42), 58%. There were five false-negative results, 2 with TL and 3 with DS, and 1 false-positive TL. Discussion: immunocytochemistry performed on the ThinPrep Processor showed equal or greater intensity and distribution of proper staining when compared to direct smears with the following advantages: (1) cleaner background, easier to interpret; (2) less abs required in a smaller area; (3) IPX can be done on Papanicolaou-stained thin layer slides; (4) thin layer slides can be modified for multiple abs tests; (5) additional thin layer slides can be prepared for ICC bases on needs. No significant differences of immunostaining were seen when comparing thin layer Papanicolaou-stained and unstained slides. Antigen retrieval offered no advantage in this study.

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1972:143105 CAPLUS
DOCUMENT NUMBER: 76:143105
TITLE: Production of lubricating oils from Lelyakovsk deposit petroleum
AUTHOR(S): Rudakova, N. Ya.; Sheremeta, B. K.; Ostrovskaya, Z. N.; Gamolina, L. N.
CORPORATE SOURCE: USSR
SOURCE: Neftepererab. Neftekhim. (Kiev) (1971), (6), 27-9
CODEN: NEFNBY
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB From the fractions b. 300-500.degree. and from the residue b. >500.degree., the industrial, motor, and aviation lubricating oils ASp-6, ASp-10, DSp-8, **DSp-11**, IS-20, IS-50, and MS-20 were prepd. The conditions of their prepn. from the new petroleum deposit are briefly stated and their properties tabulated.

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1971:44842 CAPLUS
DOCUMENT NUMBER: 74:44842
TITLE: Protective properties of liquid protective lubricants and inhibitors under tropical conditions
AUTHOR(S): Korsakov, K. K.; Putilov, V. E.
CORPORATE SOURCE: USSR
SOURCE: Zashch. Metal. (1970), 6(6), 744
CODEN: ZAMEA9
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB Samples of cast iron SCh 15-32, steel Kh18N9T, Al alloy AMTs, steel St.3, Cu, steel 38KhMYuA, bronze AMts-9-2, steel St.45, and brass AB2 were exposed to tropical conditions to det. the protective properties of some lubricants and inhibitors of corrosion. After a year exposure the only lubricant that gives pos. results is K-17. The application of NG-203A, NG-203B, NG204Y, SPI-11, and **DSp-11** with 10% AKOR-1 is of no effect on the corrosion behavior of the metals. When using inhibitors such as KhTsA, corrosion phenomena are obsd. on the brass, bronze, Cu, St.3, St.45, and 38KhMYuA. The surface corrosion is even more intensive when applying paraffin-impregnated paper and GZh-2 as inhibiting agent.

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1968:97273 CAPLUS

DOCUMENT NUMBER: 68:97273
TITLE: Adsorption and corrosion activity of diesel oils
AUTHOR(S): Sevast'yanov, S. I.
CORPORATE SOURCE: Mosk. Inzh.-Ekon. Inst. im. Ordzhonikidze, Moscow, USSR
SOURCE: Fiz.-Khim. Mekh. Mater. (1967), 3(6), 675-81
CODEN: FKMAAJ
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB The effects of diesel oils with complex additives on the mech. properties and endurance of pistons, bearings, and crankshafts of diesel engines were studied. The antifriction layer of bearings is usually attacked, being exposed to cyclic loadings and in contact with oils contg. surface- and corrosion-active components either introduced with the additives or created during exploitation. If instead of D-11 oil without additives, activated oils **Dsp-11**, M-12B, and M-12V are used, the rate of destruction is nearly 3 times as great. It seems that new bearings are less sensitive to the effect of oils due to a more homogeneous distribution of load (if repaired cranks are not well adjusted, the pulse loading becomes very pronounced, so that old engines are more susceptible to failure). The replacement of pure diesel oil D-11 by activated ones also changes the working conditions of crankshafts. The no. of cranks changed is directly proportional to the time of service, indicating the fatigue character of their failure. When activated oils are used instead of D-11, the rate of destruction is increased 30-50%. The same effect appears in the case of pistons.

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1968:41946 CAPLUS
DOCUMENT NUMBER: 68:41946
TITLE: Evaluation of the corrosion properties of diesel oils under laboratory conditions
AUTHOR(S): Sevast'yanov, S. I.
SOURCE: Khim. Tekhnol. Topl. Masel (1967), 12(10), 48-52
CODEN: KTPMAG
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB The corrosiveness of diesel oils D-11, **Dsp-11**, and M-12V, at 140.degree. on Pb increased in time, but not in proportion with the time of oxidn. By raising the temp. to 200.degree., the corrosiveness increased 3-4 times for the 1st 2 oils and .apprx.60 times for M-12V. This high increase was produced not only by the activation of the oxidn. process at a higher temp., but also by the decompn. of the oil additives, TsIATIM-339 (I) and esp. VNII NP-360 (II), at 140 and 170-180.degree., resp., producing very corrosive products. At oxidn. periods of 50 hrs., the most corrosive oil was **Dsp-11** at 140.degree. and at 200.degree., M-12V. The additives increased the diesel oil corrosiveness. By adding 3% I or 8% II to **Dsp-11**, the corrosion of Pb at 200.degree. increased 2.5-3-fold. The addn. of 8% II to M-12 increased the corrosiveness on Pb 4-5-fold. The addn. of 0.02% Cu naphthenate markedly increased oil corrosiveness. Exploitation performances of oils with additives I, II, and AzNII-7 showed that 2-3 times more crankshaft bearings of a diesel motor were put out of service as compared with the same oil without additives. These results coincided with that of the lab. corrosion tests at 200.degree. during 50 hrs. but not with those obtained by GOST 8245-56 or the oxidn. tests at 140.degree. during 25 hrs. with catalyst. Oils whose corrosiveness was detd. on Pb plates at 200.degree. during 50 hrs. was >1 mg./cm.2 hr. are considered to be corrosive. 9 references.

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1964:89852 CAPLUS
DOCUMENT NUMBER: 60:89852

ORIGINAL REFERENCE NO.: 60:15654a-c
TITLE: Effect of the coking capacity of the deasphaltizate on the yield and quality of the residual component of diesel oil
AUTHOR(S): Kazanskii, V. L.; Badyshtova, K. M.; Pisarchik, A. N.; Chesnokov, A. A.; Denisenko, K. K.
SOURCE: Tr. Kuibyshevsk. Gos. Nauchn.-Issled. Inst. Neft. Prom. (1962), (16), 36-43
From: Ref. Zh., Khim. 1963, Abstr. No. 12P257.
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB The coking capacity of **DSP-11** diesel oil, obtained from the eastern petroleum, produced by compounding the distillate and residual components, was detd. by the coking capacity of the residual component which was obtained by the selective purification of the deasphaltized petroleum asphalt with phenol and the subsequent deparaffination of the raffinate. Under lab. conditions, residual components were obtained from 3 samples of deasphaltized petroleum asphalt with different coking capacities (1.25, 1.52, and 1.9%) which were obtained under industrial conditions. Residual components of the required quality (coking capacity of 0.62-0.63%) were obtained only from deasphaltized asphalt with a coking capacity of 1.25 and 1.52%. From that with a capacity of 1.9%, in spite of an increased consumption of phenol (up to 400% as compared to 280 and 320% for those with coking capacities of 1.25 and 1.52%, resp.), a residual component with an increased coking capacity was obtained (0.81%). The best yield of residual component (coking capacity 0.63%) was obtained from deasphaltized asphalt with a coking capacity of 1.25-15.8% of the starting asphalt. The yield of residual component (coking capacity 0.81%) from the asphalt with a coking capacity of 1.9%, using 400% phenol, was 13.9%. A decrease in the coking capacity of the deasphaltized asphalt was desirable in working plants.

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1962:424319 CAPLUS
DOCUMENT NUMBER: 57:24319
ORIGINAL REFERENCE NO.: 57:4934b-d
TITLE: Production of lubricating oils from Mukhanov Devonian crude oil
AUTHOR(S): Kazanskii, V. L.; Badyshtova, K. M.; Denisenko, K. K.
SOURCE: Novosti Neft. i Gaz. Tekhn. Neftepererab. i Neftekhim. (1961), (No. 4), 6-11
From: Ref. Zh., Khim. 1962, Abstr. No. 4M142.
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB A study was made of the processing of light, sulfurous, highly paraffinic Mukhanov Devonian crude oil. Oils IS-20, IS-45, AS-9.5, and **DSP-11** obtained from this petroleum are not inferior to those from Tuimazy crude oil with respect to physicochem. properties and chem. compn., but have a higher S content. Preliminary engine tests showed that AS-5, AS-9.5, **DSP-11**, and DSP-8 behave in engines as do oils obtained from a mixt. of sulfurous crude oils (Tuimazy Bavly). An advantage of processing Mukhanov crude into lubricating oils is that, besides giving the same total yield of lubricating oil as Tuimazy oil, the yield of deasphalted and phenol-refined products is considerably greater. Mukhanov crude oil can completely replace Tuimazy Devonian oil in the production of lubricating oils; in converting oil-processing app. to Mukhanov crude oil, no essential changes in the tech. processes are necessary.

=> s dsp-11 dual specificity polypeptide?

L5 0 DSP-11 DUAL SPECIFICITY POLYPEPTIDE?

=> s dual specificity polypeptide? MAP kinase
L6 0 DUAL SPECIFICITY POLYPEPTIDE? MAP KINASE

=> s dual specificity polypeptide? and map kinase
L7 0 DUAL SPECIFICITY POLYPEPTIDE? AND MAP KINASE

=> s dual specificity polypeptide? and kinase
L8 0 DUAL SPECIFICITY POLYPEPTIDE? AND KINASE

=> s dual specificity polypeptide? and phosphatase
L9 1 DUAL SPECIFICITY POLYPEPTIDE? AND PHOSPHATASE

=> d 19 ibib ab

L9 ANSWER 1 OF 1 BIOTECHDS COPYRIGHT 2002 THOMSON DERWENT AND ISI
ACCESSION NUMBER: 2002-01808 BIOTECHDS

TITLE: New human **dual specificity polypeptides** and nucleic acids for diagnosis of disease and treatment of e.g. liver disorders; vector-mediated gene transfer and expression in mammal cell, antibody, ribozyme, antisense triple helix and transgenic animal for gene therapy

AUTHOR: Meyers R A
PATENT ASSIGNEE: Millennium-Pharm.
LOCATION: Cambridge, MA, USA.
PATENT INFO: WO 2001073059 4 Oct 2001
APPLICATION INFO: WO 2001-US9477 23 Mar 2001
PRIORITY INFO: US 2000-191858 24 Mar 2000
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2001-611635 [70]

AB An isolated nucleic acid (I, human 21117 cDNA with a 3,554, 1,998, 1,114 or 672 bp DNA sequence fully defined) encoding a dual specificity **phosphatase** (human 38692 cDNA) with a 666 or 223 amino acid protein sequence fully defined is claimed. Also claimed are: a mammal host cell containing (I); an antibody that binds to (II); production of (II) by culturing the host cell and recovering (II) from the culture medium; detection of (II) in a sample using the antibody; a method for modulating the activity or expression of (II) using a compound (antibody); modulating the proliferation, survival or differentiation of a 38692 or 21117-expressing cell by contacting the cells with a compound (peptide, phosphopeptide, antibody, antisense, ribozyme, triple helix and/or nucleic acid) that modulates (II); transgenic animals; and prevention or therapy of a disorder caused by aberrant activity or expression of (I) or (II). The antibody can be used for the detection of (II) and the nucleic acids for detecting (I) for diagnosing diseases. The above is important for hematopoietic, liver or cellular proliferative or differentiative disorder diagnosis and gene therapy.

=> s (dsp-11 or dsp-11 polypeptide or dual specificity polypeptide?) and dna
L10 3 (DSP-11 OR DSP-11 POLYPEPTIDE OR DUAL SPECIFICITY POLYPEPTIDE?)
AND DNA

=> d his

(FILE 'HOME' ENTERED AT 16:00:12 ON 09 DEC 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, BIOTECHDS' ENTERED AT
16:01:04 ON 09 DEC 2002

L1 10 S DSP-11 OR DSP-11 POLYPEPTIDE OR DUAL SPECIFICITY POLYPEPTIDE?
L2 10 DUP REM L1 (0 DUPLICATES REMOVED)
L3 10 S (DSP-11 OR DSP-11 POLYPEPTIDE OR DUAL SPECIFICITY POLYPEPTIDE

L4 10 DUP REM L3 (0 DUPLICATES REMOVED)
 L5 0 S DSP-11 DUAL SPECIFICITY POLYPEPTIDE?
 L6 0 S DUAL SPECIFICITY POLYPEPTIDE? MAP KINASE
 L7 0 S DUAL SPECIFICITY POLYPEPTIDE? AND MAP KINASE
 L8 0 S DUAL SPECIFICITY POLYPEPTIDE? AND KINASE
 L9 1 S DUAL SPECIFICITY POLYPEPTIDE? AND PHOSPHATASE
 L10 3 S (DSP-11 OR DSP-11 POLYPEPTIDE OR DUAL SPECIFICITY POLYPEPTIDE)

=> s luche ralf m/au

L11 25 LUCHE RALF M/AU

=> dup rem l11

PROCESSING COMPLETED FOR L11

L12 23 DUP REM L11 (2 DUPLICATES REMOVED)

=> s l12 and dsp

L13 16 L12 AND DSP

=> s l12 and dsp-11

L14 1 L12 AND DSP-11

=> d l14

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

AN 2001:64167 CAPLUS

DN 134:126840

TI Protein and cDNA sequences of a novel human protein **DSP-11** with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof

IN **Luche, Ralf M.**; Wei, Bo

PA Ceptyr, Inc., USA

SO PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001005983	A1	20010125	WO 2000-US19710	20000719
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1200602	A1	20020502	EP 2000-950452	20000719
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRAI US 1999-144557P P 19990720

WO 2000-US19710 W 20000719

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l13 1-16 ibib ab

L13 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:256483 CAPLUS

DOCUMENT NUMBER: 136:290009

TITLE: Protein and cDNA sequences of a novel human protein

DSP-16 with dual-specificity MAP kinase
 phosphatase activity, and therapeutic uses thereof
 INVENTOR(S): **Luche, Ralf M.**; Wei, Bo
 PATENT ASSIGNEE(S): Ceptyr, Inc., USA
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026997	A2	20020404	WO 2001-US30124	20010925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001094744	A5	20020408	AU 2001-94744	20010925
US 2002137170	A1	20020926	US 2001-964277	20010925
PRIORITY APPLN. INFO.:			US 2000-235487P	P 20000926
			WO 2001-US30124	W 20010925

AB The invention provides protein and cDNA sequences of a novel human protein
DSP-16, which has sequences homol. with dual-specificity MAP
 kinase phosphatase. The protein **DSP-16** may be used, for
 example, to identify antibodies and other agents that inhibit **DSP**
 -16 activity. Semiquant. PCR results show significantly higher levels of
DSP-16 mRNA in tissues of skeletal muscles. The invention further
 relates to the uses of protein **DSP-16** for modulating cell
 proliferation, differentiation and survival.

L13 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:240816 CAPLUS
 DOCUMENT NUMBER: 136:274309
 TITLE: Protein and cDNA sequences of the novel protein
DSP-15 from human and mouse, with
 dual-specificity MAP kinase phosphatase activity, and
 therapeutic uses thereof

INVENTOR(S): **Luche, Ralf M.**; Wei, Bo
 PATENT ASSIGNEE(S): Ceptyr, Inc., USA
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024740	A2	20020328	WO 2001-US29406	20010919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2002182203 A1 20021205 US 2001-955732 20010918
 AU 2001091146 A5 20020402 AU 2001-91146 20010919
 PRIORITY APPLN. INFO.: US 2000-233833P P 20000919
 US 2001-955732 A 20010918
 WO 2001-US29406 W 20010919

AB The invention provides protein and cDNA sequences of novel human and mouse protein **DSP-15**, which has sequences homol. with dual-specificity MAP kinase phosphatase. The protein **DSP-15** may be used, for example, to identify antibodies and other agents that inhibit **DSP-15** activity. Semiquant. PCR results show significantly higher levels of **DSP-15** mRNA in tissues of skeletal muscles. The invention further relates to the uses of protein **DSP-15** for modulating cell proliferation, differentiation and survival.

L13 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:816882 CAPLUS
 DOCUMENT NUMBER: 135:353855
 TITLE: Protein and cDNA sequences of a novel human protein **DSP-14** with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof
 INVENTOR(S): **Luche, Ralf M.**; Wei, Bo
 PATENT ASSIGNEE(S): Ceptyr, Inc., USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083723	A2	20011108	WO 2001-US14076	20010501
WO 2001083723	A3	20020502		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002102693 A1 20020801 US 2001-847519 20010501

PRIORITY APPLN. INFO.: US 2000-201322P P 20000502

AB The invention provides protein and cDNA sequences of a novel human protein **DSP-14**, which has sequences homol. with dual-specificity MAP kinase phosphatase. The protein **DSP-14** may be used, for example, to identify antibodies and other agents that inhibit **DSP-14** activity. Semiquant. PCR results show significantly higher levels of **DSP-14** mRNA in tissues of skeletal muscles. The invention further relates to the uses of protein **DSP-14** for modulating cell proliferation, differentiation and survival.

L13 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:582056 CAPLUS
 DOCUMENT NUMBER: 135:163437
 TITLE: Protein and cDNA sequences of novel human proteins **DSP-12** and **DSP-13** with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof
 INVENTOR(S): **Luche, Ralf M.**; Wei, Bo
 PATENT ASSIGNEE(S): Ceptyr, Inc., USA

SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001057221	A2	20010809	WO 2001-US3429	20010201
WO 2001057221	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2001049358 A1 20011206 US 2001-775925 20010201

PRIORITY APPLN. INFO.: US 2000-179886P P 20000202

AB The invention provides protein and cDNA sequences of novel human proteins **DSP-12** and **DSP-13**, which have sequences homol. with dual-specificity MAP kinase phosphatase. The proteins **DSP-12** and **DSP-13** may be used, for example, to identify antibodies and other agents that inhibit **DSP-12** or **DSP-13** activity. RT-PCR anal. shows **DSP-12** and **DSP-13** mRNAs in all human tissues analyzed, including brain, thymus, placenta, skeletal muscle, heart, pancreas, testis, adipose and liver. The invention further relates to the uses of proteins **DSP-12** and **DSP-13** for modulating cell proliferation, differentiation and survival. In addn., the invention also provides protein and cDNA sequences of **DSP-13** splice variant.

L13 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:64167 CAPLUS

DOCUMENT NUMBER: 134:126840

TITLE: Protein and cDNA sequences of a novel human protein **DSP-11** with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof

INVENTOR(S): **Luche, Ralf M.**; Wei, Bo

PATENT ASSIGNEE(S): Ceptyr, Inc., USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005983	A1	20010125	WO 2000-US19710	20000719

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1200602 A1 20020502 EP 2000-950452 20000719

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL
PRIORITY APPLN. INFO.: US 1999-144557P P 19990720
WO 2000-US19710 W 20000719

AB The invention provides protein and cDNA sequences of a novel human protein **DSP-11**, which has sequences homol. with dual-specificity MAP kinase phosphatase. The protein **DSP-11** may be used, for example, to identify antibodies and other agents that inhibit **DSP-11** activity. North blotting results show significantly higher levels of **DSP-11** mRNA in tissues of human kidney and liver. The invention further relates to the uses of protein **DSP-11** for modulating cell proliferation, differentiation and survival. In addn., the invention also provides protein and cDNA sequences of a mouse **DSP-11** variant.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:31658 CAPLUS

DOCUMENT NUMBER: 134:96286

TITLE: Protein and cDNA sequences of a novel human and mouse protein **DSP-3** with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof

INVENTOR(S): **Luche, Ralf M.**; Wei, Bo

PATENT ASSIGNEE(S): Ceptyr, Inc., USA

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001002582	A1	20010111	WO 2000-US18207	20000629
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2000060092	A2	20001012	WO 2000-US9185	20000407
WO 2000060092	A3	20010104		
WO 2000060092	C2	20020829		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
WO 2001002581	A1	20010111	WO 2000-US10868	20000420
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,			

WO 2001002582 A1 20010111 WO 2000-US18207 20000629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1196598 A1 20020417 EP 2000-943359 20000629

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:

US 1999-142338P P 19990702
WO 2000-US9185 A 20000407
US 1999-128225P P 19990407
WO 2000-US10868 A 20000420
WO 2000-US18207 W 20000629

AB The invention provides protein and cDNA sequences of a novel human protein **DSP-3**, which has sequences homol. with dual-specificity MAP kinase phosphatase. The protein **DSP-3** may be used, for example, to identify antibodies and other agents that inhibit **DSP-3** activity. North blotting results show significantly higher levels of **DSP-3** mRNA in tissues of heart, liver, skeletal muscle and pancreas. The invention further relates to the uses of protein **DSP-3** for modulating cell proliferation, differentiation and survival.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:772772 CAPLUS

DOCUMENT NUMBER: 133:330559

TITLE: Protein and cDNA sequences of a novel human protein **DSP-5** with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof

INVENTOR(S): **Luche, Ralf M.**; Wei, Bo

PATENT ASSIGNEE(S): Ceptyr, Inc., USA

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000065069	A1	20001102	WO 2000-US11665	20000426

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-131156P P 19990427
US 2000-564357 A 20000424

AB The invention provides protein and cDNA sequences of a novel human protein **DSP-5** and its splicing variant, which have sequences homol. with dual-specificity MAP kinase phosphatase. The protein **DSP-5** may be used, for example, to identify antibodies and other agents that inhibit

DSP-5 activity. North blotting results show significantly higher levels of DSP-5 mRNA in tissues of human brain, thymus and testis. The invention further relates to the uses of protein DSP-5 for modulating cell proliferation, differentiation and survival.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:772771 CAPLUS

DOCUMENT NUMBER: 133:330558

TITLE: Protein and cDNA sequences of a novel human protein DSP-10 with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof

INVENTOR(S): Luche, Ralf M.; Wei, Bo

PATENT ASSIGNEE(S): Ceptyr, Inc., USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000065068	A1	20001102	WO 2000-US10966	20000420
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1173587	A1	20020123	EP 2000-928331	20000420
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1999-130806P P 19990423

WO 2000-US10966 W 20000420

AB The invention provides protein and cDNA sequences of a novel human protein DSP-10, which has sequences homol. with dual-specificity MAP kinase phosphatase. The protein DSP-10 may be used, for example, to identify antibodies and other agents that inhibit DSP-10 activity. North blotting results show significantly higher levels of DSP-10 mRNA in tissues of human skeletal muscle and liver. The invention further relates to the uses of protein DSP-10 for modulating cell proliferation, differentiation and survival.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:756875 CAPLUS

DOCUMENT NUMBER: 133:318308

TITLE: Protein and cDNA sequences of a novel human protein DSP-8 with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof

INVENTOR(S): Luche, Ralf M.; Wei, Bo

PATENT ASSIGNEE(S): Ceptyr, Inc., USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063393	A1	20001026	WO 2000-US10508	20000419
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1173586	A1	20020123	EP 2000-926122	20000419
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1999-130173P P 19990420
WO 2000-US10508 W 20000419

AB The invention provides protein and cDNA sequences of a novel human protein **DSP-8**, which has sequences homol. with dual-specificity MAP kinase phosphatase. The protein **DSP-8** may be used, for example, to identify antibodies and other agents that inhibit **DSP-8** activity. North blotting results show significantly higher levels of **DSP-8** mRNA in tissues of testis. The invention further relates to the uses of protein **DSP-8** for modulating cell proliferation, differentiation and survival.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:725785 CAPLUS

DOCUMENT NUMBER: 133:291978

TITLE: Protein and cDNA sequences of a novel human protein **DSP-9** with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof

INVENTOR(S): **Luche, Ralf M.**; Wei, Bo

PATENT ASSIGNEE(S): Ceptyr, Inc., USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000060100	A1	20001012	WO 2000-US9321	20000407
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1169459	A1	20020109	EP 2000-920216	20000407
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

JP 2002540796 T2 20021203 JP 2000-609590 20000407

PRIORITY APPLN. INFO.: US 1999-128203P P 19990407
WO 2000-US9321 W 20000407

AB The invention provides protein and cDNA sequences of a novel human protein **DSP-9**, which has sequences homol. with dual-specificity MAP kinase phosphatase. The protein **DSP-9** may be used, for example, to identify antibodies and other agents that inhibit **DSP-9** activity. North blotting results show significantly higher levels of **DSP-9** mRNA in tissues of human skeletal muscle, brain, thymus, ovary and testis. The invention further relates to the uses of protein **DSP-9** for modulating cell proliferation, differentiation and survival.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:725784 CAPLUS

DOCUMENT NUMBER: 133:306352

TITLE: Protein and cDNA sequences of a novel human protein **DSP-4** with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof

INVENTOR(S): **Luche, Ralf M.**; Wei, Bo

PATENT ASSIGNEE(S): Ceptyr, Inc., USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000060099	A1	20001012	WO 2000-US9313	20000407
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1171614	A1	20020116	EP 2000-921870	20000407
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002540795	T2	20021203	JP 2000-609589	20000407
PRIORITY APPLN. INFO.:			US 1999-128204P	P 19990407
			WO 2000-US9313	W 20000407

AB The invention provides protein and cDNA sequences of a novel human protein **DSP-4**, which has sequences homol. with dual-specificity MAP kinase phosphatase. The protein **DSP-4** may be used, for example, to identify antibodies and other agents that inhibit **DSP-4** activity. North blotting results show significantly higher levels of **DSP-4** mRNA in tissues of human skeletal muscle and thymus. The invention further relates to the uses of protein **DSP-4** for modulating cell proliferation, differentiation and survival.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:725783 CAPLUS

DOCUMENT NUMBER: 133:291977

TITLE: Protein and cDNA sequences of a novel human protein **DSP-7** with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof

INVENTOR(S): **Luche, Ralf M.**; Wei, Bo

PATENT ASSIGNEE(S): Ceptyr, Inc., USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000060098	A1	20001012	WO 2000-US9257	20000407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1171613	A1	20020116	EP 2000-921835	20000407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002540794	T2	20021203	JP 2000-609588	20000407
PRIORITY APPLN. INFO.:			US 1999-128207P	P 19990407
			US 1999-135757P	P 19990525
			WO 2000-US9257	W 20000407

AB The invention provides protein and cDNA sequences of a novel human protein **DSP-7**, which has sequences homol. with dual-specificity MAP kinase phosphatase. The protein **DSP-7** may be used, for example, to identify antibodies and other agents that inhibit **DSP-7** activity. North blotting results show significantly higher levels of **DSP-7** mRNA in tissues of human skeletal muscle and testis. The invention further relates to the uses of protein **DSP-7** for modulating cell proliferation, differentiation and survival.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:725778 CAPLUS

DOCUMENT NUMBER: 133:291976

TITLE: Protein and cDNA sequences of a novel human protein **DSP-3** with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof

INVENTOR(S): Luche, Ralf M.; Wei, Bo

PATENT ASSIGNEE(S): Ceptyr, Inc., USA

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000060092	A2	20001012	WO 2000-US9185	20000407
WO 2000060092	A3	20010104		
WO 2000060092	C2	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,				

ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO 2001002581 A1 20010111 WO 2000-US10868 20000420

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001002582 A1 20010111 WO 2000-US18207 20000629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-128225P P 19990407
US 1999-142338P P 19990702
WO 2000-US9185 A 20000407
WO 2000-US10868 A 20000420

AB The invention provides protein and cDNA sequences of a novel human protein **DSP-3**, which has sequences homol. with dual-specificity MAP kinase phosphatase. The protein **DSP-3** may be used, for example, to identify antibodies and other agents that inhibit **DSP-3** activity. North blotting results show significantly higher levels of **DSP-3** mRNA in tissues of heart, liver, skeletal muscle and pancreas. The invention further relates to the uses of protein **DSP-3** for modulating cell proliferation, differentiation and survival.

L13 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:688380 CAPLUS

DOCUMENT NUMBER: 133:248094

TITLE: Protein and cDNA sequences of a novel human protein **DSP-2** with dual-specificity MAP kinase phosphatase activity, and therapeutic uses thereof

INVENTOR(S): **Luche, Ralf M.**; Wei, Bo

PATENT ASSIGNEE(S): Ceptyr, Inc., USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056899	A1	20000928	WO 2000-US7589	20000322
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,			

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1165805 A1 20020102 EP 2000-919530 20000322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
JP 2002539792 T2 20021126 JP 2000-606758 20000322
PRIORITY APPLN. INFO.: US 1999-125957P P 19990324
US 2000-527376 A 20000316
WO 2000-US7589 W 20000322

AB The invention provides protein and cDNA sequences of a novel human protein
DSP-2, which has sequences homol. with dual-specificity MAP kinase
phosphatase. The protein **DSP-2** may be used, for example, to
identify antibodies and other agents that inhibit **DSP-2**
activity. North blotting results show significantly higher levels of
DSP-2 mRNA in tissues of the immune system and testis. The
invention further relates to the uses of protein **DSP-2** for
modulating cell proliferation, differentiation and survival.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:646042 CAPLUS
DOCUMENT NUMBER: 133:236826
TITLE: **DSP-1** dual-specificity phosphatase
INVENTOR(S): **Luche, Ralf M.; Wei, Bo**
PATENT ASSIGNEE(S): Ceptyr, Inc., USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000053636	A2	20000914	WO 2000-US6154	20000308
WO 2000053636	A3	20010215		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-123255P P 19990308
AB Comps. and methods are provided for the treatment of conditions assocd.
with cell proliferation, cell differentiation and/or cell survival. In
particular, the dual-specificity phosphatase **DSP-1**, and
polypeptide variants thereof that stimulate dephosphorylation of
DSP-1 substrates, are provided. The polypeptides may be used, for
example, to identify antibodies and other agents that inhibit **DSP**
-1 activity. The polypeptides and agents may be used to modulate cell
proliferation, cell differentiation and cell survival for such disorders
include cancer, graft-vs-host disease, autoimmune disease, allergies,
metabolic disease, and abnormal cell growth or proliferation, and cell
cycle abnormalities..

=> d his

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, BIOTECHDS' ENTERED AT
16:01:04 ON 09 DEC 2002

L1 10 S DSP-11 OR DSP-11 POLYPEPTIDE OR DUAL SPECIFICITY POLYPEPTIDE?
L2 10 DUP REM L1 (0 DUPLICATES REMOVED)
L3 10 S (DSP-11 OR DSP-11 POLYPEPTIDE OR DUAL SPECIFICITY POLYPEPTIDE
L4 10 DUP REM L3 (0 DUPLICATES REMOVED)
L5 0 S DSP-11 DUAL SPECIFICITY POLYPEPTIDE?
L6 0 S DUAL SPECIFICITY POLYPEPTIDE? MAP KINASE
L7 0 S DUAL SPECIFICITY POLYPEPTIDE? AND MAP KINASE
L8 0 S DUAL SPECIFICITY POLYPEPTIDE? AND KINASE
L9 1 S DUAL SPECIFICITY POLYPEPTIDE? AND PHOSPHATASE
L10 3 S (DSP-11 OR DSP-11 POLYPEPTIDE OR DUAL SPECIFICITY POLYPEPTIDE
L11 25 S LUCHE RALF M/AU
L12 23 DUP REM L11 (2 DUPLICATES REMOVED)
L13 16 S L12 AND DSP
L14 1 S L12 AND DSP-11

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
160.65	161.07


FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-14.87	-14.87

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:12:16 ON 09 DEC 2002

[HOME](#) [HELP](#) [FEEDBACK](#) [SUBSCRIPTIONS](#) [ARCHIVE](#) [SEARCH](#)Institution: US PATENT & TRADEMARK OFFIC || [Sign In as Individual](#)

Selected Abstracts

[Download ALL Selected Citations to Citation Manager](#)

Returned: 1 citations and abstracts. Click on down arrow or scroll to see abstracts.

MF Bonaldo, G Lennon, and MB Soares

Normalization and subtraction: two approaches to facilitate gene discovery

Genome Res. 6: 791-806.

Abstract 1 of 1

Genome Research, Vol 6, 791-806, Copyright © 1996 by Cold Spring Harbor Laboratory Press

ARTICLES

Normalization and subtraction: two approaches to facilitate gene discovery

MF Bonaldo, G Lennon and MB Soares

Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, New York, USA.

Large-scale sequencing of cDNAs randomly picked from libraries has proven to be a very powerful approach to discover (putatively) expressed sequences that, in turn, once mapped, may greatly expedite the process involved in the identification and cloning of human disease genes. However, the integrity of the data and the pace at which novel sequences can be identified depends to a great extent on the cDNA libraries that are used. Because altogether, in a typical cell, the mRNAs of the prevalent and intermediate frequency classes comprise as much as 50-65% of the total mRNA mass, but represent no more than 1000- 2000 different mRNAs, redundant identification of mRNAs of these two frequency classes is destined to become overwhelming relatively early in any such random gene discovery programs, thus seriously compromising their cost-effectiveness. With the goal of facilitating such efforts, previously we developed a method to construct directionally cloned normalized cDNA libraries and applied it to generate infant brain (INIB) and fetal liver/spleen (INFLS) libraries, from which a total of 45,192 and 86,088 expressed sequence tags, respectively, have been derived. While improving the representation of the longest cDNAs in our libraries, we developed three additional methods to normalize cDNA libraries and generated over 35 libraries, most of which have been contributed to our integrated Molecular Analysis of Genomes and Their Expression (IMAGE) Consortium and thus distributed widely and used for sequencing and mapping. In an attempt to facilitate the process of gene discovery further, we have

also developed a subtractive hybridization approach designed specifically to eliminate (or reduce significantly the representation of) large pools of arrayed and (mostly) sequenced clones from normalized libraries yet to be (or just partly) surveyed. Here we present a detailed description and a comparative analysis of four methods that we developed and used to generate normalize cDNA libraries from human (15), mouse (3), rat (2), as well as the parasite *Schistosoma mansoni* (1). In addition, we describe the construction and preliminary characterization of a subtracted liver/spleen library (INFLS-SI) that resulted from the elimination (or reduction of representation) of -5000 INFLS-IMAGE clones from the INFLS library.

[HOME](#) [HELP](#) [FEEDBACK](#) [SUBSCRIPTIONS](#) [ARCHIVE](#) [SEARCH](#)

[GENES & DEVELOPMENT](#) [LEARNING & MEMORY](#) [PROTEIN SCIENCE](#) [GENOME RESEARCH](#)

Copyright © 2002 by Cold Spring Harbor Laboratory Press.